Unknown

Dataset Information

0

The novel sigma-2 receptor ligand SW43 stabilizes pancreas cancer progression in combination with gemcitabine.


ABSTRACT:

Background

Sigma-2 receptors are over-expressed in proliferating cancer cells, making an attractive target for the targeted treatment of pancreatic cancer. In this study, we investigated the role of the novel sigma-2 receptor ligand SW43 to induce apoptosis and augment standard chemotherapy.

Results

The binding affinity for sigma-2 ligands is high in pancreas cancer, and they induce apoptosis with a rank order of SV119 < SW43 < SRM in vitro. Combining these compounds with gemcitabine further increased apoptosis and decreased viability. Our in vivo model showed that sigma-2 ligand treatment decreased tumor volume to the same extent as gemcitabine. However, SW43 combination treatment with gemcitabine was superior to the other compounds and resulted in stabilization of tumor volume during treatment, with minimal toxicities.

Conclusions

This study shows that the sigma-2 ligand SW43 has the greatest capacity to augment gemcitabine in a pre-clinical model of pancreas cancer and has provided us with the rationale to move this compound forward with clinical investigations for patients with pancreatic cancer.

SUBMITTER: Hornick JR 

PROVIDER: S-EPMC3106998 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC3817331 | biostudies-literature
| S-EPMC5868285 | biostudies-literature
| S-EPMC6920852 | biostudies-literature
| S-EPMC3251632 | biostudies-literature
| S-EPMC9473340 | biostudies-literature
| S-EPMC4688079 | biostudies-literature
| S-EPMC6077122 | biostudies-literature
| S-EPMC7409345 | biostudies-literature
| S-EPMC3422102 | biostudies-literature
| S-EPMC10265583 | biostudies-literature